Plus Therapeutics (NASDAQ:PSTV) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Plus Therapeutics (NASDAQ:PSTV) had its price objective lifted by investment analysts at Ascendiant Capital Markets from $19.00 to $20.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other research firms have also recently weighed in on PSTV. HC Wainwright lowered their target price on shares of Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating on the stock in a research note on Friday, March 28th. D. Boral Capital reissued a “buy” rating and set a $9.00 price target on shares of Plus Therapeutics in a report on Friday, March 28th.

Plus Therapeutics Stock Performance

NASDAQ:PSTV opened at $0.66 on Monday. The stock has a 50-day simple moving average of $0.96 and a two-hundred day simple moving average of $1.15. The firm has a market capitalization of $11.20 million, a PE ratio of -0.26 and a beta of 0.68. Plus Therapeutics has a 52-week low of $0.24 and a 52-week high of $2.67.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The company had revenue of $1.80 million during the quarter, compared to the consensus estimate of $1.19 million. Equities analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.